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Abstract
Background: Peptidyl-prolyl isomerase cyclophilin A (CypA) plays important roles in signaling, protein translocation,
inflammation, and cancer formation. However, little is known about the mechanisms by which CypA exerts its effects.
C57BL/6 Ppia (encoding CypA)-deficient embryonic fibroblasts show reduced activation of the nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-kB), the p65/RelA subunit, suggesting that CypA may mediate modulation of NF-kB
activity to exert its biological effects.
Methodology: Western blotting and qRT-PCR analyses were used to evaluate the association of CypA deficiency with
reduced activation of NF-kB/p65 at the protein level. GST pull-down and co-immunoprecipitation were used to examine
interactions between CypA and p65/RelA. Truncation mutants and site-directed mutagenesis were used to determine the
sequences of p65/RelA required for interactions with CypA. Enhancement of p65/RelA nuclear translocation by CypA was
assessed by co-transfection and immunofluorescent imaging. Treatment of cells with cycloheximide that were harvested at
various time points for Western blot analyses was carried out to evaluate p65/RelA protein stability. The functional activity
of NF-kB was assessed by electrophoretic mobility-shift assays (EMSA), luciferase assays, and changes in expression levels of
target genes.
Results: GST pull-down assays in vitro and co-immunoprecipitation analyses in vivo provided evidence for protein-protein
interactions. These interactions were further supported by identification of a CypA-binding consensus-like sequence within
NF-kB subunit p65 at the N-terminal 170–176 amino acid residues. Significantly, CypA provided stability for NF-kB p65 and
promoted NF-kB p65 nuclear translocation, resulting in increased nuclear accumulation and enhanced NF-kB activity.
Conclusions: Our findings revealed important mechanisms that regulate NF-kB activation, and offer new insights into the
role of CypA in aberrant activation of NF-kB-mediated signaling for altered expression of its target genes, resulting in
pathological effects in various diseases.
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Introduction
Nuclear factor kB (NF-kB) is a set of multifunctional
transcription factors that regulate expression of genes involved in
numerous normal cellular activities [1,2]. In addition to the well-
established role of NF-kB in both immunity and inflammation,
deregulation of NF-kB signaling is associated with cancer
malignancies, diabetes, and atherosclerosis, further emphasizing
the wide spectrum of roles it plays in control of normal growth,
tissue homeostasis, and diseases [3,4,5]. A heterodimeric complex
of p65/RelA and p50 is the most common form of NF-kB in
mammalian cells, and is commonly referred to as NF-kB. Given
the protein functions of NF-kB to positively regulate gene
expression, there is an inhibitory kB (IkB) family of NF-kB
inhibitory proteins called IkBs, which retain NF-kB dimers in the
cytoplasm of unstimulated cells [6]. A myriad of endogenous and
exogenous stimuli, such as tumor necrosis factor alpha (TNF-a)
and interleukin 1b (IL-1b) are capable of inducing activation of the
IkB kinase (IKK) complex, which leads to ubiquitin-dependent
degradation of IkBa. NF-kB is then free to shuttle into the nucleus
and bind to specific sequences in the promoter or enhancer regions
of its target genes [7].
Although the molecular events that control translocation of NF-
kB from the cytoplasm to the nucleus are well characterized [7],
knowledge concerning the regulation of NF-kB’s activity inside the
nucleus still remains largely unclear. NF-kB is believed to recruit
co-factors to form a much higher order transcription complex than
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previously expected [8]. Among the well-characterized NF-kB co-
activators, p300/CREB-binding protein (CBP) appears to be a
basal component of a functional NF-kB transcription complex
[9,10]. A recent report demonstrated that LRP16 integrates into
the NF-kB transcriptional complex by associating with its p65
component, and is required for its functional activation [11].
CypA is a member of the peptidyl-prolyl isomerase (PPIase)
family, a group of proteins that catalyze cis-trans isomerization of
peptidyl-prolyl bonds during protein folding and/or conforma-
tional changes [12,13]. CypA was first identified as the primary
intracellular target of the immunosuppressive drug, CsA [14]. The
immunosuppressive activity of CsA is thought to result from
engagement of calcineurin by the CsA-CypA complex [15], an
observation supported by the finding that CypA knockout mice are
resistant to immunosuppression by CsA [16]. One of the other
inhibitory effects of CsA on T cell proliferation is to inhibit the
early phase of NF-kB/RelA activation by CD28 costimulatory
signaling to reduce the IL-2 expression [17]. In addition, CsA
affected not only immune cells but also on non-lymphoid lineages
and induced insensitiveness to inflammatory cytokines, especially
to TNF-a. It has been demonstrated that CsA inhibited TNF-a-
triggered MCP-1 induction via unfolded protein response (UPR)-
mediated suppression of NF-kB. This suppression of NF-kB by
UPR was, at least in part, via induction of C/EBP family members
[18].
Several lines of research have revealed that PPIase such as
CypA may function as molecular signaling ‘‘switches’’ that can act
as novel molecular timers to help control the amplitude and
duration of a cellular process [19]. Moreover, the role of CypA
nuclear translocation, CypA’s participation in activation of other
factors or their nuclear translocation also impacts various cellular
functions [20–23]. One recent report demonstrated that knock-
down of CypA inhibited signal transducer and activator of
transcription 3 (Stat3) interleukin-6-induced tyrosine phosphory-
lation and nuclear translocation, resulting in altered gene
expression in myeloma cell lines [24]. In rheumatoid arthritis
patients, over-expressed extracellular CypA stimulates production
of inflammatory cytokines such as TNF-a, IL-1b, IL-8, monocyte
chemoattractant protein-1 (MCP-1), and matrix metalloproteinase
9 (MMP-9) [25]. These extracellular CypA-stimulated products
could arise through a pathway that is dependent on NF-kB
activation. Similarly, stably expressed CypA in the SK-Hep1 cell
line revealed that the intracellular CypA up-regulates the
expression of many cytokine-related genes such as IL-8, IL-1b,
IL-6, CXCL1, CXCL2, and CXCL3 [26]. These up-regulated
cytokines and chemokines may confer tumor cell growth
advantage in the neoplastic microenvironment. We have reported
that NF-kB accumulation and activation is tightly regulated by
intracellular CypA, which suggests that CypA may be an
important contributor to aberrant activation of NF-kB in cancer
[27].
Materials and Methods
Compounds and Animals
Cyclosporin A (CsA) was purchased from Sigma-Aldrich (St.
Louis, MO). Sanglifehrin A (Sfa) was kindly provided by Novartis
Pharmaceuticals (Basel, Switzerland) dissolved in DMSO at
1023 mol/l and stored at 220uC. Samples were diluted freshly
in culture medium at the concentrations indicated. We purchased
129s6/svEV Ppia+/2 mice from Jackson Laboratory and back-
crossed to C57BL/6 Ppia+/+ mice for eight generations before use
in our experiments. All animal studies were carried out in strict
accordance with experimental protocols that were approved by the
Institutional Animal Care and Use Committee at the University of
California, Los Angeles. UCLA’s animal welfare assurance
number with Department of Health and Human Services Office
of Laboratory Animal Welfare is A3196-01. All surgery was
performed under sodium pentobarbital anesthesia, and all efforts
were made to minimize suffering.
Cell Culture and Preparation of Nuclear and Cytoplasmic
Extracts
Mouse embryonic fibroblasts (MEFs) were isolated from embryos
at embryonic day (E13.5) of pregnant C57BL/6 Ppia+/2 mice as
described [28]. MEFs were cultured in DMEM-high glucose
medium supplemented with 20% FBS and antibiotics (penicillin
and streptomycin) (Invitrogen, Grand Island, NY).
C2C12 (a murine myoblast cell line), 293T (a human kidney cell
line), and HeLa (a human cervical carcinoma cell line) were
cultured in DMEM-high glucose medium (Invitrogen) supple-
mented with 10% FBS (Invitrogen) and antibiotics penicillin and
streptomycin (Invitrogen). All cells were cultured at 37uC with 5%
CO2 in a humidified incubator. Preparation of nuclear and
cytoplasmic extracts was carried out as described previously [29].
Aliquots of extracts were used for electrophoretic mobility-shift
assays (EMSA).
GST Pull-Down Assays, Co-Immunoprecipitation, and
Immunoblot Analysis
GST pull-down assays and co-immunoprecipitation (Co-IP)
were carried out as described previously [29,30]. Briefly, 800 mg of
cell lysate was incubated with anti-myc or anti-HA antibodies (Cell
Signaling Technology, Danvers, MA) at 4uC overnight in a clinical
rotor. Protein A/G PLUS-agarose beads were then added to the
mixture and the tubes were briefly centrifuged at 1000 g at 4uC for
30 seconds to precipitate the beads bound to the Ag-Ab complex.
The beads were washed extensively. After the final wash, the beads
were centrifuged at 10,000 g for one minute, and all the liquid was
thoroughly removed. Fifty mL of SDS sample loading buffer
containing 10% b-mercaptoenthanol was then added to the
agarose beads and heated at 95uC for 5 minutes. The denatured
proteins were subjected to Western blot analysis probing with anti-
HA or anti-myc antibody.
Electrophoretic Mobility-shift Assays (EMSAs) and
Luciferase Analysis
Nuclear extracts were prepared from Ppia+/+ and Ppia2/2
MEFs, and aliquots of extracts were used for EMSA assays. EMSA
was performed using the Light Shift Chemiluminescent EMSA Kit
(Pierce Biotechnology, Rockford, IL) according to the manufac-
turer’s instructions. In brief, 100 fmol of biotin end-labeled probe
was incubated with 15 mg of nuclear extract, and then electro-
phoresed on a native polyacrylamide gel. The DNA was
transferred to a nylon membrane, UV cross-linked, probed with
the streptavidin-horseradish peroxidase conjugate, and chemilu-
minescent substrate was used for detection. 59-biotin labeled NF-
kB oligo, 59-AGTTGAGGGGACTTTCCCAGGC-39, was pur-
chased from Sigma-Aldrich. For competition experiments, 100-
fold molar excess of unlabeled oligo was used.
Luciferase reporter assays were carried out as described
previously [27]. The luciferase reporter plasmids, pGL4 nf-kb-
Luc with consensus NF-kB binding sequence GGGACTTTCC
and its mutant with mutated sequence (CTCACTTTCC), were
transfected into HeLa, MEFs, or U87vIII cells with Renilla
luciferase plasmid, using lipofectamine 2000 (Invitrogen, Carlsbad,
CA). Firefly and Renilla luciferase activity were measured with the
CypA Associates with NF-kB Activation
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dual-luciferase reporter assay system (Promega, Madison, WI).
Results are presented as relative reporter activity after normali-
zation to the Renilla luciferase activity.
Constructs and Site-Directed Mutagenesis
Mutagenesis of p65 DNA sequences was synthesized using a
conventional PCR method with primers specifically designed to
amplify the targeted mutation sites. The targeted amino acid
residues were at 170, 172, and 176 in the sequence of
PSGRPLRLP (aa 168–176) of p65, a potential binding sequence
for CypA. All primers were designed using oligo synthesis (Sigma-
Aldrich, St. Louis, MO) to contain restriction enzyme recognition
sequences for cloning and the necessary nucleic acid mutations in
order to introduce the amino acid changes post-translation. Two
constructs containing the mutation sites, spinning amino acid
residues 2–221 and 2–551, were constructed by two sets of primers
in two separate PCR reactions, then ‘‘sewn’’ together with a third
PCR reaction. For generation of the HA-2-221 (G170A/P172A/
P176A) mutant, the first set of primers (F: 59-AAACTCGAGATG-
tatccatatgacgtcccagactctgccGGATCCGACGAA-CTGTTCCCC-
CTC-39 and R: 59-GATGAGAAAGGACAGGtgcCAGGCGG-
AGggcCC-TggcTGATG-39) were used for amplification with a
template of a previously constructed p65 2–221. The second set of
primers (F: 59-ATCAgccAGGgccCTCCGCCTGgcaCCT-G-
TCCTTTCTCATC-39 and R: 59-GACAAGCTTTTATTTC-
TGCACCTTGTCACACA-G-39) were used with the same
template to amplify the second segment. Lastly, the two PCR
products were used as the template with the forward primer from
the first reaction and the reverse primer from the second reaction
sewn together to generate the HA-p65 2–221 mutated fragment.
This fragment contains the BamHI DNA recognition sequence on
the 59 end and the HindIII recognition sequence on the 39 end,
which was cloned into HindIII/BamH1 cloning sites of vector
pcDNA3.1 (-) (Invitrogen). Ten mM of dNTP mix and platinum
Pfx polymerase were used with the supplied buffer and salt
solutions to ensure high accuracy and fidelity of the PCR
amplification (all from Invitrogen).
The HA-p65 (2–551) (G170A/P172A/P176A) mutant was
generated using similar techniques; i.e., sewing two fragments
together to form the HA-p65 (2–551) mutant. The first fragment
was the final product from the first synthesis of HA-p65 (2–221),
and the second fragment was generated with a plasmid containing
full-length HA-p65 as the template. The forward primer 59-
ATCAgccAGGgccCTCCGCCTGgcaCCTGTCCTTT-CTCAT-
C-39 and reverse primer 59-GACAAGCTTTTAGGAGCTGAT-
CTGACTCA-GCAG-39 were used to create the desired muta-
tions in the second fragment. Afterwards, the two created PCR
products were mixed as a template for amplification with the
forward primer, which was used to generate the first HA-p65 (2–
221) mutant fragment, and the reverse primer, which was used for
the second PCR product, the p65 (170–551) mutant fragment.
The final amplified full-length HA-p65 (2–551) also contained the
BamHI site on the 59 end and the HindIII site at the 39 end for
cloning into a vector.
Protein Stability Assays
Comparison of p65 and its mutant for stability, HA-tagged p65
or its mutant HA-tagged p65 (G170A/P172A/P176A), were
transfected into 293T or MEF (Ppia2/2) cells with HA-LacZ for
24 hr. Cells were treated with 5 mg/ml cycloheximide (EMD
Biosciences, San Diego, CA) and harvested at the various time
points, followed by immunoblotting with anti-HA antibody and
semi-quantification with ImageJ.
To determine whether p65 degradation was due to the function
of ubiquitin proteasomes, the proteasome inhibitor MG132 (EMD
Biosciences) and cycloheximide were added to the 24 hr post-
transfected cells and harvested at indicated time points, followed
by Western blot analysis.
Reverse Transcription and Quantitative Real-Time PCR
(qRT-PCR) Analysis
Real time RT-PCR was used to analyze the RNA levels of p50
and p65 in MEFs, and of IL-1b, IL-6, and IL-8 in U87vIII cells.
Using the cDNA synthesized from the SuperScript III First-Strand
Synthesis System as templates, individual specific primers (p65 F,
59-GACGACTGTTCCCCCTC-39 and R, 59-CCTCGCACTT-
GTAGCGG-39; p50 F, 59-GCAAACCTGGGAATACTTCAT-
GTGACTAAG-39 and R, 59-ATAGGCAA-CCTCAGAATG-
CACCAGAAGTCC-39; IL-1b F, 59- TGCGTGTTGAAAGAT-
GATAA-G-39 and R, 59- TTGGGGAACTGGGCAGAC-39; IL-
6 F, 59-CTCCAGAACAGATTT-GAGAGTAGTG-39 and R, 59-
TTGTGGTTGGGTCAGGGGTG-39; IL-8 F, 59-GGGTT-
GTGGAGAAGTTTTTG-39 and R, 59-GTTTCACTGGCAT-
CTTCACTG-39) were added to each template and mixed with
the Power SYBR Green PCR Master Mix (Life Technologies,
Gaitherburg, MD). The reactions were performed using the 7300
Real-Time PCR System instrument (Applied Biosystems, Foster
City, CA). The samples were incubated in 96-well optical plates at
95uC for 10 minutes, followed by 40 cycles at 95uC for 15 seconds
and 60uC for 10 seconds. The threshold cycle (Ct) was determined
using default threshold settings, and the Ct value was defined as
the fractional cycle number at which the fluorescence passes the
fixed threshold.
Statistical Analysis
In vitro experiments were performed in triplicate and repeated
at least twice; a representative experiment (mean 6 SE) was
selected for the figures. Statistical significance of differences
observed in experimental data compared with control was
determined by the t test or one-way ANOVA statistical analysis.
The minimal level of significance was *p,0.05 and **p,0.01.
Results
Down-Regulated NF-kB/p65 Correlates with CypA
Deficiency
We have demonstrated that RNA interference knock-down of
endogenous CypA (CypA Kd) in glioblastoma cells led to impaired
NF-kB activity and significantly attenuated NF-kB-dependent
gene expression [27]. To determine whether NF-kB activity is also
reduced in CypA-deficient mice or other cell lines, we measured
basal levels of the nuclear NF-kB subunit, p65, in mouse
embryonic fibroblasts (MEFs) isolated from cyclophilin A (CypA)
knockout (Ppia2/2) mice and the CypA knocked-down mouse
myoblast cell line, C2C12. Western blot analysis revealed that
nuclear NF-kB/p65 levels, but not the other subunits of NF-kB,
were lower in Ppia2/2 MEFs and CypA Kd C2C12 cells
compared to those in wild-type cells (Figs. 1A, 1B). These results
suggest that the CypA KO or Kd was specifically associated with
lower levels of p65, which is a subunit of multifunctional
transcription factor NF-kB that regulates expression of genes
involved in numerous normal cellular activities [31]. Furthermore,
data obtained from qRT-PCR indicated that decreased NF-kB/
p65 does not occur at the transcriptional level (Fig. 1C), suggesting
that down-regulated NF-kB/p65 could occur at posttranslational
levels. To exam whether cyclosporine A (CsA) and a non-
immunosuppressive analog, sanglifehrin A (Sfa), could also
CypA Associates with NF-kB Activation
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suppress p65/Rel A, we treated MEF with CsA (1.0 mM) and Sfa
(100 nM) to inhibit CypA isomerase activity, followed by
examining p65/RelA expression levels in cytoplasmic and nuclear
extracts. The results demonstrated that reduced p65/RelA
expression levels by treatment with CypA inhibitors are similar
to the reduced p65 levels in CypA Kd or CypA-KO cells,
suggesting that CypA isomerase activity is correlated with
expression levels of p65RelA (Fig. 1D).
CypA binds to p65, A Subunit of NF-kB
There is growing evidence for a role for peptidyl-prolyl
isomerases (PPIases) in transcriptional control. Various PPIases
were found to interact with transcription factors and affect their
activity [32,33,24]. To explore the possibility of CypA interacting
with NF-kB components, we performed GST-CypA pull-down
assays, using cell lysates from the glioblastoma cell line, U87vIII.
The pull-down proteins were subjected to immunoblot analysis
with anti-p65 antibody. As shown in Fig. 2A, CypA interacted
with p65. To confirm the results obtained from the GST-CypA
pull-down assay, in vivo interactions of expressed HA-p65 and
myc-CypA were performed by co-immunoprecipitation. Cell
lysates prepared from 293T cells expressing HA-p65 and myc-
CypA plasmids were immunoprecipitated with anti-HA antibody
(Roche Applied Science, Madison, WI) or anti-myc antibody (Cell
Signalling Technology, Beverly, MA), followed by immunoblot
analysis for myc-CypA and HA-p65, respectively. As shown in
Fig. 2B, immunoprecipitation with anti-HA antibody, followed by
Western blotting with anti-myc antibody or vice versa, demon-
strated that CypA co-immunoprecipitates with p65.
Identification of a CypA-Interacting Domain of p65, A
Subunit of NF-kB
To localize the region of p65 that directly interacts with CypA,
we generate three HA-tagged truncation mutants and subjected
them to in vivo interactions with myc-CypA by co-immunopre-
cipitation. Truncation 1 (A-fragment), spanning amino acid
residues 1–221, contains one potential consensus sequence for
CypA-binding; truncation 2 (B-fragment), spanning amino acid
residues 220–335, contain a previously identified Pin1-binding site
[33]; and truncation 3 (C-fragment), spanning amino acid residues
334–551, contains one potential consensus sequence for CypA-
binding (Figs. 2C, D). Cell lysates prepared from cells expressing
wild-type HA-tagged p65 or HA-tagged truncation fragments and
myc-CypA were immunoprecipitated with anti-myc antibody,
followed by immunoblotting with anti-HA antibody. The results
clearly demonstrated that truncation A-fragment contains a CypA-
binding site (Fig. 2C, lane 6).
To further identify the functional binding site of CypA on the
truncation A-fragment, we constructed two truncation mutants,
HA-2-169 and HA-170-335, from the truncation A-fragment. Cell
lysates containing expressed HA-2-169 and myc-CypA or HA-
170-335 and myc-CypA had no interaction between either
truncated mutants with CypA, suggesting that the binding site
identified on the truncation A-fragment had been disrupted
(Fig. 2C, lanes 16 and 17). Moreover, we constructed a HA-tagged
expression plasmid with a mutation (G170A/P172A/P176A) in
the potential CypA-binding consensus sequence, GRPLRLP,
spanning amino acid residues 170–176. Cell lysates prepared
from 293T cells expressing HA-tagged 2–221mut and 2–551mut
lost their co-immunoprecipitation with co-expressed myc-CypA
(Fig. 2C, lanes 26 and 29). These results demonstrated that amino
Figure 1. CypA deficiency reduces activated NF-kB/p65 (RelA) expression. (A) Western blot analysis of CypA, NF-kB subunits and their
inhibitory protein, IkBa. Cytoplasmic extracts isolated from MEFs and C2C12 cells were immunoblotted for IkBa, and GDPH was used as internal
control. Nuclear extracts prepared from MEFs and C2C12 cells were subjected to Western blot analysis to detect p65/RelA, p50, RelB, and p52
expression levels. p84 served as an internal control. Ppia+/+ and Ppia2/2 represent CypA WT and CypA KO, respectively. SC is a scrambled clone, and
1C2 and 2B6 are C2C12 CypA Kd clones. (B) Semi-quantitative analysis of relative expression levels of p65/RelA in MEFs (Ppia+/+ vs Ppia2/2) and
C2C12 cells (WT, SC vs 1C2 and 2B6). (C) qRT-PCR analysis of relative mRNA expression levels of p65/RelA and p50 between Ppia+/+ and Ppia2/2MEFs.
(D) p65/RelA expression levels in MEF cytoplasmic extract (CE) and nuclear extracts (NE) upon treatment cells with CsA and Sfa.
doi:10.1371/journal.pone.0096211.g001
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acid residues between 170 and 176 in the p65 molecule are the
functional binding sites of CypA.
CypA Provides Protein Stability for NF-kB/p65 and
Enhances Nuclear Translocation of p65
To directly address the possibility that CypA is necessary for
protein stability of p65, we determined the stability of ectopically
Figure 2. Interaction of CypA with the NF-kB subunit, p65/RelA. (A) GST pull-down assays. GST-CypA was immobilized on GSH-sepharose 4B
beads, then incubated with glioblastoma cell line U87vIII whole-cell lysates. The complexes were resolved by SDS-PAGE and transferred to
nitrocellulose membranes, followed by probing with anti-p65/RelA antibody. (B) Co-immunoprecipitation of myc-tagged CypA (myc-CypA) with HA-
tagged p65/RelA. Cell extracts prepared from myc-CypA and HA-p65/RelA co-transfected cells were subjected to immunoprecipitation by anti-HA
antibody, or with anti-myc antibody, followed by immunoblotting with anti-myc or anti-HA antibodies. (C) Mapping the region of p65/RelA required
for interaction with CypA. The HA-tagged various truncations were co-trasfected with myc-CypA into 293T cells. Cell lysates were
immunoprecipitated with anti-myc antibody, followed by immunoblotting with anti-HA antibody. As shown in lane 6, the truncation of 2–221
retains binding activity. Furthermore, site-directed mutagenesis of p65’s amino acid residues G170A/P172A/P176A prevented binding and interaction
between NF-kB/p65 with CypA (compare lane 26 with lane 23; and compare lane 29 with lane 18). (D) Schematic representation of p65/RelA, its
various truncations and site-directed mutants, and their binding activity.
doi:10.1371/journal.pone.0096211.g002
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expressed HA-tagged p65 and its mutant, p65 (G170A/P172A/
P176A) (hereafter referred to as p65 mutant), which lacks CypA
binding capability. HA-tagged LacZ was used as a control for co-
transfection with HA-tagged p65 or its mutant. Co-transfected
cells were treated with cyclohexamide for various time periods,
followed by immunoblotting with anti-HA antibody and semi-
quantification with ImageJ to determine relative p65 protein
stability in the presence or absence of CypA binding. The results
demonstrated that the half-life of the p65 mutant was considerably
shorter (Fig. 3A), and amino residues 170–176 in p65 are
necessary for CypA binding and for regulation of p65 protein
stability. To provide evidence further, similar experiments were
performed in MEF (Ppia2/2) cells. The results clearly show that
both WT and mutant p65 have shorter half lifes in the CypA-
negative MEF cells (Fig. 3B), suggesting that CypA is required for
their stability.
It has been demonstrated that p65 protein stability is regulated
by the ubiquitin-mediated proteolytic pathway [33]. Therefore, it
is feasible to test whether ubiquitin-mediated proteolytic degrada-
tion is responsible for the unstability of the p65 mutant, which is
subjected to proteolysis in the absence of CypA protection. We
compared p65 mutant protein stability in the presence or absence of
proteasome inhibitor MG-132 in 293T cells and MEF (Ppia2/2).
Cells treated with MG-132 had prolonged half-life of the p65
mutant protein (Figs. 3C, D), suggesting involvement of ubiquitin-
mediated proteolysis.
Figure 3. p65/RelA protein stability. (A) Comparison of p65/RelA and its mutant (p65 G170A/P172A/P176A) (p65/RelAm) stability in 293T cells.
(B) Comparison of p65/RelAm stability in the presence or absence of proteasome inhibitor MG-132 in 293T cells. (C) Comparison of p65/RelA and its
mutant stability in CypA-deficient MEF. (D) Comparison of p65/RelAm stability in the presence or absence of MG132 in CypA-deficient MEF. Relative
protein stabilities were semi-quantified with ImageJ.
doi:10.1371/journal.pone.0096211.g003
CypA Associates with NF-kB Activation
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To examine the effects of CypA on p65 localization, red
fluorescent protein-tagged p65 (pRed-p65) or its mutant (pRed-
p65-mut) expression plasmids were co-transfected with the GFP-
CypA expression plasmid into HeLa cells, followed by fluorescence
microscopy to determine p65 localization. Cells stained with 49,6-
Diamidino-2-Phenylindole (DAPI) were used as an indicator for
nuclear localization. The results clearly demonstrated that CypA
enhances Red-p65 but not the Red-p65mut for translocation into
the nucleus (Figs. 4A and 4B). To examine the requirement of
endogenous CypA for regulating p65 nuclear translocation,
CypA+/+ and CypA2/2 MEFs were treated with TNF-a for
30 min, followed by immunofluorescence staining with anti-p65
antibody. TNF-a-untreated MEFs served as controls. Relative p65
fluorescence intensities in the nucleus were shown in Ppia+/+ MEF
but not in the Ppia2/2 MEF after 30 min of TNF-a treatment
(Fig. 4C). Together, these findings indicate that CypA enhances
nuclear translocation of NF-kB/p65. To examine whether ectopic
expression of CypA into CypA-negative MEF (Ppia2/2) could
restore p65/RelA expression levels similar to those expressed in
WT MEF (Ppia+/+), we performed Western blot analyses to
compare expression levels of both CypA and p65/RelA between
WT and CypA transfected CypA-deficient MEF (Ppia2/2). The
restored expression levels of CypA and p65 (both CE and NE) are
similar to those expressed in WT MEF (Fig. 4D). These results
further supported the notion that CypA provides protein stability
for NF-kB/p65 and enhances nuclear translocation of p65/RelA.
Endogenous CypA is Necessary for Full Activation of NF-
kB in Response to Cytokine Stimulation
Ectopic expression of CypA enhances NF-kB activity (Fig. 5A).
CypA R55A mutant retains less than 1% of the WT catalytic
efficiency was used as controls. These results supported our
observation for the effects of CypA on NF-kB nuclear transloca-
tion (Figs. 4A, B). Given that CypA enhances p65 nuclear
localization, key questions raised are whether endogenous CypA
is required for p65 nuclear localization, protein stability, and NF-
kB signaling. To address these questions, we first compared NF-
kB activation between wild-type C2C12 cells and CypA Kd
clones, 1C2 and 2B6, in response to cytokines such TNF-a and IL-
1b. Cells were transfected with wild-type kB-Luc and mutant
reporter for 24 hrs, and incubated with cytokines for 1 hr,
followed by luciferase activity analysis (Fig. 5B). The results
indicated that CypA Kd cells are resistant to cytokine-stimulated
full activation of NF-kB, suggesting that CypA is required for full
Figure 4. CypA enhances NF-kB/p65 nuclear translocation. (A) Nuclear translocation of p65/RelA but not the CypA-binding site mutant (p65/
RelAm) induced by endogenous CypA. HeLa cells were transfected with pRed-p65/ReA and its mutant, and p65 location was determined by
fluorescence microscopy. (B) HeLa cells were co-transfected with pRed-p65/RelA or pRed-p65/RelAm and GFP-CypA, and the locations of p65 and
CypA were determined by fluorescence microscopy. (C) Comparison of the TNF-a-induced endogenous p65/RelA nuclear translocation in MEFs
isolated from WT (Ppia+/+) and CypA KO (Ppia2/2). Relative intensity of p65/RelA in the nucleus was determined by fluorescence microscopy. (D) p65/
RelA expression levels in CypA-deficient MEF were restored by ectopically expressed CypA.
doi:10.1371/journal.pone.0096211.g004
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activation of NF-kB in response to cytokine stimulation. We next
investigated the molecular mechanisms underlying the response of
WT (Ppia+/+) and CypA KO (Ppia2/2) MEFs to cytokine
signaling, and examined the levels of nuclear p65 at various time
points after cells were treated with TNF-a. Nuclear fractions
prepared at various time points were subjected to immunoblotting
with anti-p65 and histone 3 (H3) antibodies. In WT cells, cytokine-
activated nuclear p65 levels accumulated for up to 60 minutes,
while nuclear p65 was rapidly degraded in CypA-deficient MEFs
after peaking at 10 minutes, suggesting that CypA is required for
stabilized activated NF-kB/p65 (Fig. 5C). We also performed
EMSA to examine the effect of CypA on NF-kB DNA-binding
activity, and found that it was significantly increased in the TNF-
a-treated WT MEF nuclear extracts, but not in the TNF-a-treated
CypA-deficient MEF nuclear extracts (Fig. 5D). These data
indicate that endogenous CypA is required for nuclear localization
and protein stability.
To determine whether CypA Kd can affect expression of
cytokines such IL-8, IL-1 and IL-6 in the glioblastoma cell line,
U87vIII, real-time RT-PCR was performed to assess cytokine
expression in the CypA Kd single clones, Ud-12 and Ud-3, as
Figure 5. CypA is associated with NF-kB binding and transcriptional activities. (A) CypA activates kB site-mediated luciferase activity in a
dose-dependent manner. Hela cells were transfected with indicated amounts of CypA, together with pGL4 nf-kb-Luc reporter constructs for 24 hrs,
followed by luciferase activity assays. CypA (R55A) was used as negative control. (B) TNF-a-induced nuclear p65 levels degraded more quickly in MEFs
isolated from Ppia2/2 mice. MEFs were treated with TNF-a for the indicated times, and nuclear extracts were prepared for Western blot analysis for
p65 expression levels. Histone H3 protein served as an internal control. (C) Reduced NF-kB binding activity associated with CypA KO MEFs. EMSAs
were performed with nuclear extracts from MEFs isolated from WT (Ppia+/+) and CypA KO (Ppia2/2) mice. NF-kB oligos were used as a probe. For
competition experiments, nuclear extracts were pre-incubated with 100-fold molar excess of unlabeled oligos at 25uC for 10 min before addition of
labeled probes. P84 was used as an internal loading control. (D) CypA is required for cytokine-induced full activation of kB-Luc activity. C2C12 cells
and CypA Kd clones 1C2 and 2B6 were transfected with wild-type (WT) or mutant (MUT) pGL4 nf-kb-Luc reporter constructs, followed by treatment
with IL-1a or TNF-a. Cells were harvested for luciferase assays.
doi:10.1371/journal.pone.0096211.g005
Figure 6. CypA Kd-mediated down-regulation of IL-8, IL-6, and
IL-1b expression. IL-8, IL-6, and IL-1b expression levels were
determined by a quantitative real-time PCR (qRT-PCR) analysis. One
microgram of total RNA was used for cDNA synthesis with Superscript III
(Invitrogen) and the oligo(dT)15 primer. qRT-PCR was performed using
the Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City,
CA) detected by the 7300 Real Time PCR System (Applied Biosystems).
The relative expression levels of IL-8, IL-6, and IL-1b mRNA were
normalized to the internal reference 18S rRNA.
doi:10.1371/journal.pone.0096211.g006
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compared to the parental cells and scrambled clone. As shown in
Fig. 6, expression of IL-8, IL-1, and IL-6 in Ud-12 and Ud-3 cells
was significantly attenuated compared to parental U87vIII control
cells. In combination, these results and the data shown in Fig. 1
clearly demonstrate that CypA Kd results in suppressed activation
of NF-kB and down-regulates cytokines that are involved in
inflammation, proliferation, and angiogenesis [36–38].
Discussion
Knock-down and knock-out of the peptidyl-prolyl isomerase
CypA, a Ppia gene product, led to reduced NF-kB activity and
signaling output. The regulatory role of CypA on NF-kB was
further corroborated by enhanced NF-kB/p65 (RelA) nuclear
localization, stability, and the levels of NF-kB activity. These
findings highlight important functions of CypA in NF-kB
signaling, and suggest that CypA could be an important
contributor to elevated NF-kB in tumors, as previously reported
by us and others [27,34,35]. In this study, CypA was identified as a
novel interactor of the NF-kB subunit p65/RelA. Both in vitro
binding assays and in vivo co-immunoprecipitation confirmed the
physical association between CypA and NF-kB/p65. Systematic
analysis of different regions of p65/RelA that may be involved
interaction with CypA revealed that N-terminal truncation 1 (A-
fragment), spanning amino acid residues 1–221, was the only
region of p65/RelA that interacts with CypA. The NCBI Protein
Data Bank shows that truncation 1 of p65/RelA contains two
proline-rich motifs, PPHRPHP and PSGRPLRLP (Fig. 2D),
which are CypA-binding consensus sequence-like motifs. Site-
directed mutagenesis of the potential CypA-binding consensus
sequence, PSGRPLRLP, results in disruption of the protein-
protein interactions between CypA and p65/RelA. These results
demonstrated that amino acid residues between 170 and 176 in
the p65/RelA molecule are the functional binding sites of CypA.
Our data indicate that the N-terminal region of p65/RelA is
involved in its interaction with CypA. The interacting domain of
CypA (amino acid residues 1–20) does not overlap with the CsA
ligand-binding region (down-stream to H54) [29,39]; therefore,
CypA retains isomerase activity when it binds to p65/RelA. This
isomerase activity might be required for proper configuration to
stabilize proteins to avoid proteolysis of p65/RelA. Given the
ability of CypA to enhance NF-kB activity, this activation might
be independent of IkBa phosphorylation by IKK. The study
conducted in human monocytic leukemia cell line THP-1
demonstrated that CypA induces degradation of IkB and nuclear
translocation of NF-kB [23]. However, our data demonstrate that
CypA enhances NF-kB DNA-binding and transcription activity,
and increases nuclear translocation, but we did not detect
degradation of IkBa. Evidence of ectopically expressed CypA
led to reduced p65/RelA bound by IkBa. Therefore, CypA could
hijack the p65-p50 complex and translocate into the nucleus, and
the stabilized NF-kB complex leads to increased transcription
activity.
We report here for the first time that CypA is the only protein
that interacts with the N-terminal region of the RH domain of
p65/RelA. Parvulin-like human Pin1 also binds to p65/RelA at
the phosphorylated Threonine residue in the Thr254-Pro motif
[33]. Despite different substrate recognition motifs, similar
biological functions for CypA and Pin1 binding to p65/RelA
have been observed to increase p65 nuclear translocation and
protein stability, and to enhance NF-kB activity [33]. This
supports the hypothesis that PPIases have some features in
common, allowing them to occasionally complement each other.
Considerable up-regulation of CypA and Pin1 in most tumors is
frequently associated with tumor aggressiveness, which could be
due to up-regulated NF-kB activity. Therefore, these PPIases are
candidates for anti-cancer targets for intervention by small
molecule inhibitors. However, their success may well depend
upon the development of combined isozyme-, tissue-, and
organelle-specific inhibitors for enzyme-catalyzed prolyl bond
isomerizations.
Our data demonstrated that CypA Kd significantly reduces IL-1,
IL-6, and IL-8 expression, suggesting that CypA mediates NF-kB
activity to regulate its downstream gene expression. Since these
cytokines may confer tumor cell growth advantage in the neoplastic
microenvironment [36–38], a strategy to reverse these effects might
offer attractive options for novel therapeutics. In conclusion, these
findings provide definitive evidence to support the integration of
CypA into the NF-kB transcriptional complex via direct interaction
with p65/RelA and its crucial role for NF-kB accumulation and
activation inside the nucleus. Specific inhibitors for CypA in tumor
cells might represent a therapeutic target for the control of excess
NF-kB activity.
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